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Abstract
Introduction: Atrial fibrillation (AF) is the most common sustained arrhythmia.
Diabetic autonomic neuropathy (DAN) is a frequent complication of diabetes
mellitus and has a negative impact on the cardiovascular system. There are no
data about the occurrence of paroxysmal atrial fibrillation (PAF) in the population
with DAN. 
Material and methods: We analysed the data of 100 patients with PAF. The study
population was divided into three groups: group I: 28 patients with diabetes
mellitus (DM) and DAN, group II: 34 patients with DM without DAN, and group
III: 38 patients without DM. P-wave duration (FPD) and dispersion (PWD) were
measured during sinus rhythm and AF episodes were counted during 12 months
of follow-up. 
Results: Recurrence of PAF was higher in group I (47 episodes/year) compared to
groups II and III (26 and 22 episodes/year) – p < 0.01. The FPD was longer in group
I (137.4 ±12.0 ms vs. 126 ±23.0 ms in II group and 129 ±18.3 ms in group III;
p < 0.001). The PWD was longer in patients with DAN (53 ±19 ms vs. 36 ±18 ms
and 34 ±20 ms, p < 0.001).
Conclusions: The results showed that the presence of DAN caused a significant
increase in P-wave duration and dispersion, which might be responsible for the
recurrence of AF.
Key words: diabetes mellitus, autonomic nervous system, atrial fibrillation,
electrophysiology.
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia
encountered in clinical practice and is responsible for a substantial portion
of excess cardiovascular morbidity and mortality [1]. Its prevalence doubles
with each advancing decade of age, from 0.5% at the age of 50-59 years
to almost 9% at the age of 80-89 years. For men and women, respectively,
diabetes conferred a 1.4- and 1.6-fold AF risk after adjusting for other
associated conditions [2].
Diabetic autonomic neuropathy (DAN) has a significant negative impact
on the cardiovascular system. Typical findings in DAN include cardiac
arrhythmias, cardiovascular instability, exercise intolerance and also higher
mortality among diabetic patients [3]. The DAN is a frequent complication
in diabetes mellitus (DM) with a reported prevalence of 46% in DM
diagnosed less than 5 years ago and up to 70% with > 20 years of diabetes
[4]. Diagnosis of DAN is, perhaps, one of the most overlooked of all serious
Corresponding author:
Andrzej Bissinger MD, PhD
Department 
of Invasive Cardiology
and Cardiodiabetology
Medical University
113 Zeromskiego
90-549 Lodz, Poland
Fax: +48426393563
Phone: +48426393563
E-mail: abissinger@gmail.com
Clinical research
Department of Invasive Cardiology and Cardiodiabetology, Medical University, Lodz,
Poland
Submitted: 18 August 2010
Accepted: 13 December 2010
Arch Med Sci 2011; 7, 5: 806-812
DOI:  10.5114/aoms.2011.25555
Copyright © 2011 Termedia & BanachArch Med Sci 5, October / 2011 807
complications of DM. There are no data about the
occurrence of paroxysmal atrial fibrillation (PAF) in
the population with DAN. 
P-wave dispersion (PWD) is an electro  cardio  -
graphic marker that has been associated with
inhomogeneous and discontinuous propagation of
sinus impulses [5, 6]. Prolonged P-wave dispersion
is commonly found in patients with a history of PAF
[5, 7], and PWD was a clinically useful predictor of
progression from PAF to persistent AF [8].
The purpose of our study was to evaluate
whether the presence of DAN increases inhomo  -
geneous atrial conduction and recurrence of AF in
patients with DM type 2. 
Material and methods
The population in the present study comprised
patients with a history of PAF recurrences after
successful electrical cardioversion for persistent
atrial fibrillation. Cases with left ventricular systolic
dysfunction defined as left ventricular ejection
fraction < 50%, with left atrial diameter > 4.5 cm,
after myocardial infarction, with hypo- or hyper  -
thyro  idism and receiving antiarrhythmic drugs
except β-blockers were excluded. Of 108 eligible
participants, 100 complied with the study, because
they had successfully finished 12-month follow-up.
Reasons for not completing the study were as
follows: unsuccessful cardioversion after recurrence
of AF (n = 3), stroke (n = 2), patient’s refusal to
continue the study (n = 2), re-location (n = 1). 
Patients with DM history, taking oral anti-
diabetic medicine or insulin were accepted as
diabetic. On entering the study, Ewing’s tests, 
P-wave duration and dispersion measurements and
echocardiographic parameters were assessed. 
The diagnosis of DAN was established on the basis
of Ewing’s tests [4, 9] set together in Table I.
Autonomic function tests were performed in the
morning after 12-h fasting. The DAN was identified
when ≥ 3 of 5 tests were positive. 
At the time of electrocardiographic recording all
the subjects were in sinus rhythm. Simultaneously
12-lead ECG was recorded at the speed of 200 mm/s
in supine position. CardioLab v. 6.0 General Electric
Medical Systems was used for ECG recordings and
measurements. The measurements of P-wave
duration and dispersion were performed manually
by two of the investigators blinded to other patient
information. 
P-wave duration was measured from the onset
to the offset of the P-wave in the lead with the
longest P-wave. The onset and offset were defined
as the junction between the P-wave pattern and
the isoelectric line. P-wave dispersion was defined
as the difference between the maximum and
minimum P-wave duration in 12 leads. If the onset
and termination of the P-wave could not be
identified with certainty in a particular lead, the
lead was excluded from the analysis. An ECG with
measurable P waves in < 8 leads was also excluded
from the analysis. 
The study population was divided into three
groups depending on the occurrence of DM and DAN.
Group I consisted of 28 patients with DM and DAN
(19 men, 9 women, aged 69 ±7.6 years). Group II
consisted of 34 patients with DM without DAN 
(22 men, 12 women, aged 68 ±6.8 years) and 
group III consisted of 38 patients with PAF 
wit  hout DM (27 men, 11 women, aged 68 ±7.4 years). 
During 12-month follow-up the patients were
scheduled for examinations once a month at the
cardiology outpatient clinic. Twenty-four-hour Holter
electrocardiogram (ECG) monitoring was also
performed monthly. All patients were instructed
and received written information how to visit the
GP doctor and perform ECG recording in any case
of heart palpitation. The ECG recordings were made
Test Description Positive if
Expiration/Inspiration  The patient was asked to take deep breaths for   Max HR – min HR < 10 bpm
(E/I) ratio 10 min with frequency about 6 breaths/min
Valsalva maneuver The patient was asked to blow into a mercury  Max RR/min RR < 1.2
sphygmomanometer and to maintain the pressure 
at about 40 mmHg for 15 s
Postural heart rate response:  HR was measured in horizontal position and again  30th RR/15th RR < 1.0
maximum-minimum  2 min later after standing upright
(30 : 15 ratio)
Postural blood pressure  Blood pressure in the non-dominant arm was recorded  A fall of BP by 
response with a mercury sphygmomanometer first in horizontal  > 20 mmHg systolic
position and again in 1, 3 and 5 min after standing upright or > 10 mmHg diastolic
Isometric hand grip test The patient was asked to cramp dynamometer for 5 min  Diastolic BP rise < 10 mmHg
HR – heart rate (bpm), BP – blood pressure, RR – interval between successive R-waves on ECG (ms)  
Table I. Ewing’s tests and DAN diagnosis
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in all instances when clinical evaluation suggested
AF. Only ECG proven AF episodes longer than 10 s,
registered during normal or Holter ECG, were
regarded as AF recurrence.
The study was approved by the Local Ethics
Committee and all included subjects gave informed
consent. 
Statistical analysis
All numeric variables were expressed as mean ±
SD and categorical variables as percentages.
Statistical analysis was performed using Student’s
t-test, or Mann-Whitney test in the case of non-
normal distribution of values (Shapiro-Wilk test).
The groups were compared independently: group I
and II, I and III, II and III. A p value < 0.05 was
considered statistically significant.
Results
The clinical profiles of the study patients are
presented in Table II. All groups were statistically
comparable for demographic parameters, duration
and control of diabetes, coexisting diseases and
treatment. Echocardiographic parameters, parti  -
cularly left ventricular ejection fraction and left atrial
diameter, were also comparable in all patients. 
During 12-month follow-up, AF episodes were
recorded in 18 patients from group I, 12 from group
II and 14 from group III. The frequency of PAF
recurrence was significantly higher in patients with
DAN (group I) (47 episodes/year) compared to
groups II and III (26 and 22 episodes/year,
respectively) (p < 0.01). The PAF recurrence episodes
were mainly detected by Holter monitoring and
were asymptomatic in all groups. The numbers of
asymptomatic episodes were 36 in group I, 21 in
group II, and 18 in group III. Results of electro  cardio  -
graphic measurements are presented in Table III.
P-wave duration was significantly longer in
patients with DAN (137.4 ±12.0 ms vs. 126 ±23.0 ms
in DM without DAN and 129 ±18.3 ms in patients
without DM; p < 0.001). Similarly, P-wave dispersion
was longer in patients with DAN (53 ±19 ms vs. 
Parameter Group I  Group II  Group III  Value of p
DM DAN (+)  DM DAN (–)  DM (–) 
(n = 28) (n = 34) (n = 38)
Gender (female/male) 9/19 12/22 11/27 ns
Age [years] 69 ±7.6 68 ±6.8 68 ±7.4 ns
Duration of persistent AF  73 ±86 82 ±79 69 ±83 ns
before first cardioversion [days]
Duration of diabetes [years] 8.3 ±4.6 7.1 ±3.8 – ns
HbA1c [%] 8.4 ±2.1 8.6 ±1.9 5.6 ±2.3  p < 0.001 
group III vs. I and II
Body mass index (BMI) [kg/m2] 28.7 ±4.6 29.2 ±6.0 27.6 ±5.1 ns
eGFR [ml/min] 65 ±7 67 ±9 70 ±6  ns
Previous diagnosed hypertension [%] 53 56 53 ns
Hyperlipidaemia [%] 43 44 43 ns
Left ventricular ejection fraction (EF) [%] 58 ±12 54 ±17 56 ±11 ns
Left atrial diameter [cm] 4.0 ±2.3 3.8 ±3.2 4.1 ±3.2 ns
DM therapy [%]
Insulin 25 32 –
Oral anti-diabetic  75 68 –
(sulphonylureas and/or biguanides)
Concomitant medication [%]
β-blocker 68 67 70 ns
ACEI 87 84 90 ns
Diuretics 63 68 60 ns
Statins 47 57 47 ns
DM DAN (+) – diabetes mellitus with diabetic autonomic neuropathy, DM DAN (–) – diabetes mellitus without diabetic autonomic neuropathy,
DM (–) – patients without diabetes mellitus, ACEI – angiotensin-converting enzyme inhibitors, hyperlipidaemia = total cholesterol ≥ 200 mg/dl,
hypertension = blood pressure ≥ 140/90 mmHg, eGRF – estimated creatinine clearance (Cockcroft-Gault formula)
Table II. Clinical profiles of the study patients
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36 ±18 ms and 34 ±20 ms, respectively; p < 0.001).
Figures 1 and 2 present an example of P-wave
dispersion and duration, respectively. 
Discussion
In the current study, frequent recurrence of AF
and significantly longer P-wave duration and
dispersion were demonstrated in patients with DM
and DAN compared with the remaining groups. This
is the first study which shows an association
between PAF and DAN. Our results suggest that
autonomic neuropathy may be responsible for the
recurrence of AF probably through its impact on
intra- and interatrial conduction resulting in
inhomogeneous propagation of sinus impulses.
Most research has been focused on molecular and
physiological mechanisms, but the autonomic
nervous system has not been consistently viewed
as a “critical point” in the clinical approach to
patients with PAF. Coumel was the first to coin the
terms vagal and adrenergic AF in his landmark
clinical and experimental studies on autonomic
tone and AF [10, 11]. He reported that “vagal AF”
usually occurs in young patients, more frequently
men, who have no structural heart disease. It tends
to occur postprandially and at night. But “adrenergic
AF” is usually triggered by physical or emotional
stress and often occurs in the presence of heart
disease.
Interestingly, when the role of heart rate
variability (HRV) was assessed as a predictor of AF
onset in the Framingham Heart Study, autonomic
dysregulation at baseline as reflected by altered
HRV was not associated with the risk of AF. These
Parameter DM DAN (+) DM DAN (–) DM (–) Value of p
P-wave duration (FPD) [ms] 137 ±12.0 126 ±23.0 129 ±18.3 < 0.001*
P-wave dispersion (PWD) [ms] 53 ±19 36 ±18 34 ±20 < 0.001*
DM DAN (+) – diabetes mellitus with diabetic autonomic neuropathy, DM DAN (–) – diabetes mellitus without diabetic autonomic neuropathy,
DM (–) – patients without diabetes mellitus, *p – DM DAN (+) vs. DM DAN (–) and DM (–)
Table III. Results of electrocardiographic measurements
Figure 1. Example of P-wave dispersion (PWD) measurement. The longest P-wave is 168 ms in lead II, the shortest
P-wave is 107 ms in V1; PWD = 61 ms
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seemingly conflicting results are perhaps explained
by differences in the patient population, the time
frame during which HRV was measured and by the
intrinsic limitation of this technique. Therefore, in
our study Ewing’s tests, not HRV, were used to
evaluate autonomic system dysfunction. These
simple, non-invasive tests introduced in the early
1970s are still applied successfully by many
investigators [3, 12]. 
Our study suggests that inhomogeneous atrial
depolarization is the potential trigger of PAF in
patients with DAN. We used P-wave duration and
dispersion to estimate this phenomenon. There are
a lot of studies confirming the role of P-wave
duration and dispersion as non-invasive markers
associated with PAF [5, 6, 13]. P-wave duration
longer than 110 ms suggests interatrial block,
which is associated with development of atrial
fibrillation [14].
P-wave duration and dispersion were reported
to be influenced by the autonomic tone, which
induces changes in the velocity of impulse
propagation, but the results are not unequivocal.
Chema  et al. [15] showed that sympathetic
stimulation with isoproterenol or epinephrine
significantly shortened P-wave duration but 
β-adrenergic blockade prolonged it. Also there are
limited data concerning the effect of administration
of catecholamines or β-blockers on conduction
velocity. Tukek et al. reported that after the Valsalva
manoeuvre, maximum P-wave duration and PWD
increased significantly [16]. Imamoglou et al.
reported that PWD is increased in children with DM
type 1 and values for the dispersion in the diabetic
subjects were similar before and after the Valsalva
manoeuvre, whereas dispersion was found to be
significantly increased after this manoeuvre in the
controls [17]. Also, Yazici et al. reported prolongation
of PWD in DM patients; the authors of this
publication did not analyse autonomic nervous
function, but speculated that the possible
mechanism of dispersion could be atrial myopathy
and fibrosis [18].
Autonomic dysfunction in DM leading to DAN is
caused by diffuse and widespread damage of
sympathetic and parasympathetic nerves. Hypo  -
theses concerning the multiple aetiologies of DAN
include metabolic insult to nerve fibres, neuro  -
vascular insufficiency, autoimmune damage and
neurohormonal growth factor deficiency [3, 19]. The
highest resting heart rate resulting from para  -
sympathetic damage is one of the indicators of
DAN. However, heart rate may decline with
increasing severity of DAN. Fixed heart rate, defined
Figure 2. Example of P-wave duration measurement. The longest P-wave duration is 168 ms in lead II
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as unresponsiveness to moderate exercise, stress
or sleep, indicates almost complete cardiac
denervation [20]. Changes in autonomic nervous
system activity can play an important role in the
genesis of cardiac arrhythmias. Hirose et al. [21]
showed that atrial vagal denervation facilitates
initiation of AF. The study of Gould et al. [22]
provides evidence for the presence of heightened
atrial sympathetic innervation in patients with
persistent AF, suggesting that autonomic
remodelling may be part of atrial substrate for AF.
There are no data concerning effects of DAN on AF. 
Twelve years ago, Haissaguerre et al. published
a landmark observation describing the causal role
of pulmonary veins in the inception of AF [23].
However, the mechanism of impulse initiation in
the pulmonary veins has still not been defined.
There is more evidence showing that the pulmonary
veins are capable of automaticity. Specialized
cardiac cells associated with pacemaking,
resembling Purkinje cells, have been observed in
the pulmonary veins in rats, dogs and humans [24].
The intrinsic component of the autonomic nervous
system is composed of a network formed of axons
and autonomic ganglia (ganglion plexus) embedded
within epicardial fat pads located above both atria
and ventricles [25]. One important part of the
ganglion plexus has been located in close proximity
to the left atrial-pulmonary vein junction. This area
is rich in autonomic innervations. Scherlag et al.
showed that stimulation of the plexus in this
location can convert focal activity in the pulmonary
veins into AF [26]. Some research groups have
hypothesized that elimination of the ganglion
plexus, particularly at the pulmonary vein-atrial
junction, could increase the success rate of AF
ablation [27]. Also Zimmermann et al. found that in
patients with focal ectopy originating from the
pulmonary veins, sustained episodes of atrial
arrhythmias were mainly dependent on variations
of autonomic tone, with a significant shift toward
vagal predominance before AF onset [28]. Further
studies in this area are needed to elucidate the role
of autonomic nervous system dysfunction in
pulmonary vein focal activity. 
Our study revealed that patients with DAN and
paroxysmal AF had statistically significantly longer
P-wave duration and dispersion and frequent AF
recurrences. According to our knowledge, this is the
first published report concerning DAN and P-wave
duration and dispersion. 
There were some limitations in our study. We
assessed a small group of patients and therefore
no correlations were made between DAN intensity
and P-wave dispersion or duration. Because also
other factors such as serum electrolyte level,
changes in atrial volume or pressure, etc, might
have influenced P-wave duration and dispersion,
further studies are needed to determine which
other factors may affect P-wave dispersion and
duration. Finally, we analysed only ECG-proven
episodes of AF; therefore the number of AF episodes
seems to be underestimated, especially as PAF
episodes were mainly asymptomatic. 
In conclusion, the results of our study showed
that the occurrence of DAN caused a significant
increase in P-wave duration and dispersion, which
might be responsible for more frequent develo  -
pment of AF. Therefore, it seems that not DM but
diabetic autonomic neuropathy might be a possible
risk factor of AF re-initiation.
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